FDA grants accelerated approval to Nuvalent's neladalkib for ALK-positive NSCLC
NUVL•The FDA granted accelerated approval to Nuvalent's neladalkib for previously treated, locally advanced or metastatic ALK-positive non-small cell lung cancer.
NUVL•The FDA granted accelerated approval to Nuvalent's neladalkib for previously treated, locally advanced or metastatic ALK-positive non-small cell lung cancer.
The FDA granted accelerated approval to neladalkib for previously treated, locally advanced or metastatic ALK-positive non-small cell lung cancer.